Discontinued — last reported Q3 '21
Agilent Technologies Equity Securities Without Readily Determinable Fair Value - Cumulative Impairment Loss remained flat by 0.0% to $26.00M in Q4 2025 compared to the prior quarter.
equity_securities_no_fv_impairment_cumulative| Q1 '21 | Q2 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $11.00M | $0.00 | $26.00M | $26.00M | $26.00M |
| QoQ Change | — | — | — | — | — | — | — | — | -100.0% | — | +0.0% | +0.0% |